Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
Walter ReinischWayne HellstromRadboud J E M DolhainSuresh SikkaRené WesthovensRajiv MehtaTimothy RitterUrsula SeidlerOleksandr GolovchenkoVladimir SimanenkovOlena GarmishSławomir JekaRadka MoravcováVijay RajendranFranck-Olivier Le BrunSarah ArterburnTimothy R WatkinsRobin BesuyenDirk VanderschuerenPublished in: Annals of the rheumatic diseases (2023)
Results suggest that once daily filgotinib 200 mg for 13 weeks has no measurable impact on semen parameters or sex hormones in men with active IBD or inflammatory rheumatic diseases.